COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00030108
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : March 15, 2012
National Cancer Institute (NCI)
Information provided by:
National Institutes of Health Clinical Center (CC)

Brief Summary:

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating young patients with relapsed or refractory solid tumors or leukemia.

Condition or disease Intervention/treatment Phase
Brain and Central Nervous System Tumors Childhood Germ Cell Tumor Extragonadal Germ Cell Tumor Kidney Cancer Leukemia Liver Cancer Neuroblastoma Ovarian Cancer Sarcoma Unspecified Childhood Solid Tumor, Protocol Specific Drug: ixabepilone Phase 1

Detailed Description:



  • Determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of ixabepilone in young patients with refractory solid tumors (closed to accrual as of 10/4/2007) or relapsed or refractory leukemia.
  • Determine the toxicity spectrum of this drug in these patients.
  • Determine the plasma pharmacokinetics of this drug in these patients.
  • Determine the pharmacodynamics of this drug in these patients.
  • Assess the nerve growth factor levels, before and after the initiation of this drug, as a potential surrogate marker for the development of peripheral neuropathy in these patients.


  • Determine the response of patients treated with this drug.
  • Compare the tolerability, toxicity profile, MTD, DLT, pharmacokinetics, and pharmacodynamics of this drug in young patients treated on this study vs adults with solid tumors (closed to accrual as of 10/4/2007) treated on the ongoing Medicine Branch, NCI, phase I study.
  • Assess the safety and tolerability of ixabepilone at the solid tumor MTD (expanded leukemia cohort).
  • Evaluate the plasma pharmacokinetics of in young patients with refractory or relapsed leukemia.
  • Evaluate the extent of tubulin polymerization in leukemic blasts at baseline after treatment with ixabepilone ex-vivo.
  • Compare the effects of tubulin polymerization in leukemic blasts with ixabepilone versus paclitaxel ex-vivo with an without the presence of a potent P-glycoprotein inhibitor.
  • Evaluate the activity known drug transporters in drug-resistant leukemias in leukemic blasts.

OUTLINE: This is a multicenter, dose-escalation study.

Patients receive ixabepilone IV over 1 hour on days 1-5. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of ixabepilone until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 or more of 6 patients experience dose-limiting toxicity. Intrapatient dose escalation to one dose level above the enrollment dose level is allowed in patients who have stable or responding disease or are experiencing other benefits from therapy (e.g., decrease in tumor-related pain symptoms) and who have no grade 2 or greater non-hematologic toxicity and no grade 3 or greater hematologic toxicity. Additional patients are treated at the MTD. Patients treated at the MTD may not undergo intrapatient dose escalation.

PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study within 1-2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Primary Purpose: Treatment
Official Title: Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients With Refractory Solid Tumors and Leukemias
Study Start Date : November 2001
Actual Primary Completion Date : March 2010
Actual Study Completion Date : April 2010

Primary Outcome Measures :
  1. Maximum tolerated dose and dose-limiting toxicity of ixabepilone
  2. Toxicity spectrum
  3. Plasma pharmacokinetics
  4. Pharmacodynamics
  5. Nerve growth factor levels before and after drug administration

Secondary Outcome Measures :
  1. Objective tumor response
  2. Tubulin polymerization in PBMCs prior to the start of the infusion, just before the end of the infusion, 5 hours after the end of the infusion and before the start of the infusion on day 2 of the ixabepilone on course 1

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Meets 1 of the following criteria:

    • Histologically confirmed solid tumor (closed to accrual as of 10/4/2007) that relapsed after or failed to respond to front-line curative therapy and for which no other potentially curative treatment options exist

      • Curative therapy may include surgery, radiotherapy, chemotherapy, or any combination of these modalities
      • Eligible tumor types include, but are not limited to, the following:

        • Rhabdomyosarcoma
        • Other soft tissue sarcomas
        • Ewing's sarcoma family of tumors
        • Osteosarcoma
        • Neuroblastoma
        • Wilms' tumor
        • Hepatic tumors
        • Germ cell tumors
        • Primary brain tumors

          • Histologic confirmation may be waived for brain stem or optic glioma
    • Diagnosis of relapsed or refractory leukemia

      • Patients with refractory or second or greater relapsed leukemia must have > 25% blasts in the bone marrow (M3 bone marrow) with or without active extramedullary disease (except for leptomeningeal disease)
      • Relapsed after or failed to respond to frontline curative therapy and no other potentially curative therapy (e.g., radiotherapy, chemotherapy, or any combination of these modalities) exists
    • Patients with acute promyelocytic leukemia must be refractory to treatment with retinoic acid and arsenic trioxide
    • Patients with Philadelphia chromosome positive chronic myelogenous leukemia must be refractory to imatinib
  • No active CNS leukemia (CNS3)



  • 2 to 18 (solid tumor patients [closed to accrual as of 10/4/2007])
  • 1 to 21 (leukemia patients)

Performance status:

  • For patients age 11 to 21:

    • Karnofsky 50-100%
  • For patients age 1 to 10:

    • Lansky 50-100%

Life expectancy:

  • Not specified


  • Platelet count at least 100,000/mm^3 (20,000/mm^3 for leukemia patients)
  • Hemoglobin ≥ 8.0 g/dL


  • Bilirubin less than 1.5 times upper limit of normal (ULN)
  • SGOT and SGPT less than 2.5 times ULN
  • No hepatic dysfunction that would preclude study


  • Creatinine normal for age OR
  • Creatinine clearance at least 60 mL/min
  • No renal dysfunction that would preclude study


  • No known severe prior hypersensitivity reaction to agents containing Cremophor EL
  • No clinically significant unrelated systemic illness (e.g., serious infections or other organ dysfunction) that would preclude study
  • No grade 2 or greater preexisting sensory neuropathy
  • More than 2 month since prior and no concurrent evidence of graft vs host disease
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception


Biologic therapy:

  • Recovered from all therapy-related acute toxic effects (leukemia patients only)
  • Prior epoetin alfa allowed
  • At least 3 days since other prior colony-stimulating factors (e.g., filgrastim (G-CSF), sargramostim (GM-CSF), or interleukin-11 (IL-11))
  • At least 6 months since prior bone marrow transplantation
  • At least 2 months since prior stem cell transplantation or rescue (leukemia patients)
  • At least 7 days since prior therapy with a biological agent and hematopoietic growth factor with the exception of erythropoietin
  • More than 3 weeks since prior monoclonal antibody therapy (leukemia patients only)
  • No concurrent GM-CSF or IL-11
  • No concurrent immunotherapy


  • See Disease Characteristics
  • Recovered from all therapy-related acute toxic effects (leukemia patients only)
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)
  • No other concurrent anticancer chemotherapy

Endocrine therapy:

  • Concurrent corticosteroids allowed for the control of symptoms related to tumor-associated edema in patients with brain tumors
  • Patients with brain tumors must be on a stable or tapering dose of corticosteroids for 7 days before baseline scan is performed for the purpose of assessing response to study therapy
  • Must be on a stable or tapering dose of corticosteroids for 7 days prior to study entry (leukemia patients only)


  • See Disease Characteristics
  • Recovered from all therapy-related acute toxic effects (leukemia patients only)
  • At least 4 weeks since prior radiotherapy
  • More than 2 weeks since prior local palliative radiotherapy (leukemia patients only)
  • More than 3 months since prior total-body irradiation, craniospinal radiotherapy, or radiotherapy to ≥50% of the pelvis (leukemia patients only)
  • More than 6 weeks since prior other substantial bone marrow radiotherapy (leukemia patients only)
  • No prior extensive radiotherapy (e.g., craniospinal irradiation, total body irradiation, or radiotherapy to more than half of the pelvis)
  • No concurrent anticancer radiotherapy


  • See Disease Characteristics


  • Recovered from prior therapy
  • At least 30 days since any prior investigational anticancer therapy
  • At least 1 week since prior known inhibitors of CYP3A4, including any of the following:

    • Antibiotics (i.e., clarithromycin, erythromycin, or troleandomycin)
    • Anti-HIV agents (i.e, delaviridine, nelfinavir, amprenavir, ritonavir, idinavir, saquinavir, or lopinavir)
    • Anti-fungals (i.e., itraconazole, ketoconazole, fluconazole [doses > 3mg/kg/day], or voriconazole)
    • Anti-depressants (i.e., nefaxodone or fluovoxamine)
    • Calcium channel blockers (i.e., verapamil or diltiazem)
    • Anti-emetics (i.e., aprepitant [Emend®])
    • Miscellaneous agents (i.e., amiodarone)
    • Grapefruit juice
  • No other concurrent investigational agents
  • No concurrent St. John's Wort
  • No concurrent known inhibitors of CYP3A4, including grapefruit juice
  • Concurrent other agents inducing CYP3A4 allowed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00030108

Layout table for location information
United States, District of Columbia
Children's National Medical Center
Washington, District of Columbia, United States, 20010-2970
United States, Maryland
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
Bethesda, Maryland, United States, 20892-1182
Sponsors and Collaborators
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: AeRang Kim, MD National Cancer Institute (NCI)

Publications of Results:
Layout table for additonal information Identifier: NCT00030108    
Obsolete Identifiers: NCT00025961
Other Study ID Numbers: 020031
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: March 15, 2012
Last Verified: March 2012
Keywords provided by National Institutes of Health Clinical Center (CC):
recurrent childhood rhabdomyosarcoma
childhood craniopharyngioma
recurrent neuroblastoma
recurrent childhood liver cancer
recurrent Wilms tumor and other childhood kidney tumors
childhood central nervous system germ cell tumor
recurrent osteosarcoma
unspecified childhood solid tumor, protocol specific
childhood germ cell tumor
recurrent childhood soft tissue sarcoma
childhood oligodendroglioma
childhood choroid plexus tumor
childhood grade I meningioma
childhood grade II meningioma
childhood grade III meningioma
recurrent childhood cerebellar astrocytoma
recurrent childhood cerebral astrocytoma
recurrent childhood medulloblastoma
recurrent childhood visual pathway and hypothalamic glioma
previously treated childhood rhabdomyosarcoma
recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
recurrent childhood ependymoma
childhood teratoma
childhood malignant testicular germ cell tumor
childhood malignant ovarian germ cell tumor
childhood extragonadal germ cell tumor
recurrent childhood malignant germ cell tumor
B-cell childhood acute lymphoblastic leukemia
childhood acute basophilic leukemia
childhood acute eosinophilic leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Neoplasms
Neoplasms, Germ Cell and Embryonal
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Neoplasms by Site
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Digestive System Neoplasms
Digestive System Diseases
Liver Diseases
Nervous System Diseases
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents